Goldman Sachs just upgraded this ASX 200 tech share

This could be the tech share to buy right now according to the broker.

| More on:
A man holding a cup of coffee puts his thumb up and smiles while at laptop.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The Pro Medicus Limited (ASX: PME) share price has been on fire in 2023.

Since the start of the year, the ASX 200 tech share has risen approximately 23%.

Where next for this ASX 200 tech share?

The good news for investors is that analysts at Goldman Sachs don't believe it is too late to buy Pro Medicus shares.

According to a note, the broker has upgraded the company's shares to a buy rating with a $76.00 price target.

Based on the current Pro Medicus share price of $67.94, this implies a potential upside of 12% for investors over the next 12 months.

What did the broker say?

The broker has been impressed with the health imaging technology company's recent contract wins and feels there could be more coming. It highlights that "Visage 7 looks set for a robust period of transaction revenue as PME on-boards several large accounts."

This is underpinned by the "growing importance of a radiology IT system that can materially improve efficiency" and the "competitive advantage of PME's offerings."

Goldman acknowledges that this ASX 200 tech share is not cheap on paper. However, it believes it deserves to trade at a premium. This is due to its highly profitable business, strong growth potential, and robust balance sheet.

On our estimates, PME currently trades on 63x NTM EV/EBITDA (noting we are +13-14% above EBITDA consensus in FY24/25E after incorporating the latest contract wins). Whilst it doesn't look cheap on near-term multiples: i) the business is highly profitable (>50% net margins); ii) cash flows are recurrent/long-dated in nature (5/7-year contracts); and iii) the balance sheet looks robust ($80m net cash).

Our new estimates imply a +22% EBITDA CAGR (FY23-26E), a 'multiple to growth' ratio of 2.9x, which we view as undemanding vs. ASX Healthcare on 2.2x. We view PME as the clear incumbent technology leader in a growth market with low-risk market share upside from <10% today, and the optionality to broaden/deepen into a platform solution for adjacent/complementary offerings. We upgrade to Buy.

All in all, Goldman appears to believe this could be one tech share to buy and hold.

Wondering where you should invest $1,000 right now?

When investing expert Scott Phillips has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for over ten years has provided thousands of paying members with stock picks that have doubled, tripled or even more.*

Scott just revealed what he believes could be the 'five best ASX stocks' for investors to buy right now. We believe these stocks are trading at attractive prices and Scott thinks they could be great buys right now...

See The 5 Stocks *Returns as of 30 April 2025

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended Goldman Sachs Group and Pro Medicus. The Motley Fool Australia has recommended Pro Medicus. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Technology Shares

Buy, hold, and sell ratings written on signs on a wooden pole.
Technology Shares

After surging 13% yesterday, are TechnologyOne shares a buy, hold or sell according to Macquarie?

Valuations matter when investing, and Macquarie feels no different.

Read more »

Two smiling work colleagues discuss an investment or business plan at their office.
Technology Shares

Why Goldman Sachs rates this ASX tech share as a top buy

Let's see why the broker rates this stock highly right now.

Read more »

A woman sits at her computer with her hand to her mouth and a contemplative smile on her face as she reads about the performance of Allkem shares on her computer
Technology Shares

WiseTech shares have surged 34% since April. Is it too late to buy?

Can WiseTech shares keep charging higher? Here’s what this investing expert expects.

Read more »

A man in full American NFL playing kit crouches over with his arms across his chest in a defensive stance against a dark background.
Technology Shares

ASX 300 tech stock charges 7% higher to record high on stellar results

This tech stock delivered another impressive result this morning.

Read more »

a man sits at his desk wearing a business shirt and tie and has a hearty laugh at something on his mobile phone.
Technology Shares

Up 87% in 12 months: Why this ASX tech share is still a top buy

This technology business still has loads of potential, according to a fund manager.

Read more »

a group of three cybersecurity experts stand with satisfied looks on their faces with one holding a laptop computer while he group stands in front of a large bank of computers and electronic equipment.
Technology Shares

2 ASX 200 tech stocks Morgans rates as buys

The leading broker has named a couple of shares to buy right now.

Read more »

Man smiling at a laptop because of a rising share price.
Technology Shares

Is it time to buy ASX data centre shares?

ASX data centre shares have been rebounding lately. Will they continue to?

Read more »

a group of people sit around a computer in an office environment.
Earnings Results

Guess which ASX 200 tech stock is rocketing 12% on record results

Another half, another record result from this high-quality company.

Read more »